Document is current
Any future updates will be listed below
-
Authors
Bilican, Gülden
Noor, Nurulamin M.
Haas, Stephan L.
Petrousis, Grigorios
Kirman, Derya
Moral, Kenan
Koçak, Engin
Kablan, Sevilay Erdoğan
Nemutlu, Emirhan
Kalkan, Çağdaş
Cindoruk, Mehmet
Kekilli, Murat
Karakan, Tarkan
-
Funding
Funding for this research was provided by:
Gazi University Scientific Research Projects Unit
- License Information
-
More Information
Article History
Received: 6 February 2026
Accepted: 15 May 2026
First Online: 22 May 2026
Declarations
Ethics approval and consent to Participate: The study was approved by the Ethics Committee of Gazi University Faculty of Medicine Hospital (Approval Date: March 6, 2023; Decision Number: 200). The study was conducted in accordance with the principles of the Declaration of Helsinki.Written informed consent was obtained from all participants prior to enrollment.
Consent for publication: Not applicable.
Competing interests: Dr. Nurulamin M. Noor has received educational grants and/or speaker fees from AbbVie, BMS, Celltrion, Dr Falk, Ferring, Johnson & Johnson, Lilly, Medfyle, Pfizer, Pharmacosmos, Takeda, and Tillotts. Dr. Stephan L. Haas has served as a speaker and/or advisory board member for Celltrion, Ferring, Janssen, Lilly, Mediahuset, Pfizer, Santax Medico, Takeda, and Tillotts Pharma. All other authors declare no conflicts of interest.
